Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse
Conditions
DLBCL
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
NL-Rotterdam-ERASMUSMC, Rotterdam, Netherlands
Study leads
P.J. Lugtenburg, Dr.
Principal Investigator
NL-Rotterdam-ErasmusMC